Posts by: Patricia Inacio PhD

News

A committee of the European Medicines Agency (EMA) has recommended the conditional approval of Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL). The recommendation ... Read more

October 16, 2020October 16, 2020

FDA Approves Keytruda for Adults as Second-Line Therapy for Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has expanded the use of Keytruda (pembrolizumab) as a second-line treatment for adults with relapsed or refractory classical Hodgkin’s lymphoma (cHL) for whom initial therapies ... Read more

September 18, 2020September 18, 2020

EMA to Review Opdivo-Yervoy Combo for Untreated, Inoperable Mesothelioma

News

The European Medicines Agency has agreed to review Bristol Myers Squibb’s application requesting approval for the dual immunotherapy regimen Opdivo (nivolumab) and Yervoy (ipilimumab) for untreated, inoperable malignant pleural mesothelioma (MPM). This decision ... Read more

June 26, 2020June 26, 2020

FDA Approves Keytruda for Advanced Squamous Cell Skin Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a treatment for people with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) — the second most common form ... Read more

June 15, 2020June 15, 2020

Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track

News

TVI-Brain-1, an immunotherapy being developed by TVAX Biomedical, was given fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment of glioblastoma multiforme, a deadly form of ... Read more

May 12, 2020May 12, 2020

ICT’s CAR T-cell Therapy Shows Promise in Reducing Size of Solid Tumors

News

A potential CAR T-cell therapy by Innovative Cellular Therapeutics (ICT) showed early signs of safety and efficacy, significantly reducing tumor size in four patients with thyroid or colorectal cancer, new data ... Read more

February 14, 2020February 14, 2020

Ilixadencel Improves Responses, Extends Survival in Newly-diagnosed Metastatic Kidney Cancer, Trial Results Show

News

Adding Immunicum‘s ilixadencel to standard surgical and medical treatment for newly-diagnosed metastatic renal cell carcinoma — the most common form of kidney cancer — increases patient responses, duration of response, and appears ... Read more

December 12, 2019January 6, 2020

Gut Bacteria as Means of Boosting Immunotherapy in Advanced Cancers Focus of Clinical Trial

News

Vedanta Bioscience has started a Phase 1/2 trial to test its investigational oral microbiome therapy, VE800, in combination with the immune checkpoint inhibitor Opdivo (nivolumab) as treatment for certain advanced cancers. VE800 ... Read more

November 27, 2019November 27, 2019

Surface Oncology Asking to Open Trial of Antibody Therapy for Advanced Solid Cancers

News

Surface Oncology is requesting approval to open a Phase 1/1b clinical trial testing SRF617, an anti-CD39 antibody, either alone or in combination with other cancer immunotherapies in people with advanced solid tumors. The ... Read more

October 18, 2019

First Patients Dosed in Phase 1/2 Trial Testing Galinpepimut-S, Keytruda Combo in Advanced Cancers

News

A Phase 1/2 clinical trial assessing the cancer vaccine galinpepimut-S in combination with Keytruda (pembrolizumab) as a treatment for WT-1-positive advanced cancers has started dosing patients, Sellas Life Sciences announced. ... Read more